These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16189281)

  • 1. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
    Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
    Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
    Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
    Sharma A; Yee J; Gandra SR; Khan I; Petersen J
    Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H; Decter A; Greco T; Watson SH; Kang YJ; Mody SH; Piech CT; Duh MS; Naeem A
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
    Charlesworth EC; Richardson RM; Battistella M
    Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
    Agrawal V; Mukherjee S; Kosuri R; Dumler F
    Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended dosing of darbepoetin alfa in patients with chronic kidney disease not on dialysis: a review of recent data.
    Moore T; Chookie S
    Nephrol Nurs J; 2005; 32(4):399-407. PubMed ID: 16180781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S; Spirko R; Law A; Dennis VW
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.